Abbott Agrees to Pay Over $384M to Settle Allegations Related to Contaminated Infant Formula
Abbott Laboratories (Abbott), an Illinois-based healthcare company that manufactures and sells infant formula and nutritional therapy products, has agreed to pay $384,999,040 to resolve allegations that it caused false claims to be submitted between Jan. 1, 2018, and Dec. 31, 2022, to federal and state programs arising from its failure to manufacture certain powder infant formula and nutritional therapy products...
Contenu original affiche; la traduction localisee n'est pas encore disponible.
Ce qui s'est passé
Abbott Laboratories (Abbott), an Illinois-based healthcare company that manufactures and sells infant formula and nutritional therapy products, has agreed to pay $384,999,040 to resolve allegations that it caused false claims to be submitted between Jan. 1, 2018, and Dec. 31, 2022, to federal and state programs arising from its failure to manufacture certain powder infant formula and nutritional therapy products...
Pourquoi c'est important
The development may change operating conditions or market expectations around Regulation. Further confirmation and measurable outcomes matter.
Entités concernées
Voir les preuves
1 articles · 1 publication d'origine · 1 independantes
- U.S. Department of JusticeSource primaire · Confirme · EN · 100%Abbott Agrees to Pay Over $384M to Settle Allegations Related to Contaminated Infant Formula ↗
Affirmations
- Abbott Agrees to Pay Over $384M to Settle Allegations Related to Contaminated Infant Formula Observé
Divergences
Aucune divergence importante détectée dans les preuves disponibles.
Chronologie
- Premier signalement
Mouvement de marché suivant l'événement
La réaction du marché n'est pas encore disponible pour cet actif et cette fenêtre.